Ethinylestradiol/norethisterone acetate

From Wikipedia, the free encyclopedia
(Redirected from Junel)

Ethinylestradiol /
norethisterone acetate
Combination of
Norethisterone acetateProgestogen
Clinical data
Trade namesEstrostep, FemHRT, Loestrin, Microgestin, others[1]
Other namesEE/NETA
AHFS/Drugs.comProfessional Drug Facts
License data
Routes of
By mouth (pill)
ATC code
Legal status
Legal status
CAS Number
PubChem CID
Chemical and physical data
3D model (JSmol)
  • InChI=1S/C22H28O3.C20H24O2/c1-4-22(25-14(2)23)12-10-20-19-7-5-15-13-16(24)6-8-17(15)18(19)9-11-21(20,22)3;1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,13,17-20H,5-12H2,2-3H3;1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t17-,18+,19+,20-,21-,22-;16-,17-,18+,19+,20+/m01/s1

Ethinylestradiol/norethisterone acetate (EE/NETA), or ethinylestradiol/norethindrone acetate, is a combination of ethinylestradiol (EE) and norethisterone acetate (NETA) which is used as birth control and menopausal hormone therapy.[1][2] EE is an estrogen, while norethisterone acetate (NETA) is a progestin.[1] It is taken by mouth.[1] Some preparations of EE/NETA used in birth control additionally contain an iron supplement in the form of ferrous fumarate.[3]

In 2020, it was the 45th most commonly prescribed medication in the United States, with more than 14 million prescriptions.[4][5] It is available as a generic medication.[6]

Society and culture[edit]

Brand names[edit]

Brand names of EE/NETA include Anovlar, Blisovi, Cumorit, Estrostep, FemHRT, Fyavolv, Gildess, Junel, Larin, Leribane, Loestrin, Lo Loestrin (Lo Lo), Mibelas, Microgestin, Minastrin, Norlestrin, Primodos, Taytulla, and Tri-Legest, among others.[7]

In addition, the combination is sold in the United States under the brand name FemHRT for use in menopausal hormone therapy.[8][9][2]

See also[edit]


  1. ^ a b c d "Estrogen-Progestin Combinations Monograph for Professionals". AHFS. Retrieved 28 December 2018.
  2. ^ a b Rowan JP, Simon JA, Speroff L, Ellman H (June 2006). "Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials". Clin Ther. 28 (6): 921–32. doi:10.1016/j.clinthera.2006.06.013. PMID 16860174.
  3. ^ Willihnganz M, Clayton AD (1 May 2014). Basic Pharmacology for Nurses - E-Book. Elsevier Health Sciences. pp. 648–. ISBN 978-0-323-29309-9.
  4. ^ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
  5. ^ "Ethinyl Estradiol; Norethindrone - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
  6. ^ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 3 March 2023. Retrieved 6 March 2023.
  7. ^ "Ethinyl Estradiol and Norethindrone (Professional Patient Advice)". 13 July 2019. Retrieved 10 April 2020.
  8. ^ "Drug Approval Package: Femhrt (Norethindrone Acetate & Ethinyl Estradiol) NDA #21065". U.S. Food and Drug Administration (FDA). Retrieved 28 December 2018.
  9. ^ "FemHRT- norethindrone acetate/ethinyl estradiol tablet". DailyMed. 14 November 2017. Retrieved 31 December 2019.

External links[edit]